Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huoxiang Anwei Powder is a Traditional Chinese Medicine (TCM) herbal formulation developed by Shenzhen Traditional Chinese Medicine Hospital for the treatment of *Helicobacter pylori* infection. It is typically utilized as an adjuvant therapy in combination with standard Western quadruple eradication regimens, which generally include a proton pump inhibitor, bismuth, and two antibiotics. The formulation is designed to enhance the eradication rate of the pathogen while simultaneously alleviating TCM-related syndrome symptoms, such as those associated with spleen-stomach disharmony or damp-heat. Clinical evaluation of the powder also focuses on its ability to improve patient quality of life and reduce psychological distress, including anxiety and depression, which are often comorbid with chronic gastric infections and intensive antibiotic treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huoxiang Anwei Powder.